Try to Avoid PPIs With New Hep C Med Epclusa

September 2016

Please see the October 2016 FDA advisory about the risk of Hepatitis B reactivation in some patients being treated for Hepatitis C.

Epclusa (ep-KLOO-suh, sofosbuvir/velpatasvir) will further simplify hepatitis C treatment.

So far, other recent hep C meds (Harvoni, Zepatier, etc) can only be used for certain hep C genotypes...and treatment duration varies.

But Epclusa is a one-tab, once-daily med that can be used for ANY hep C genotype...and patients use just a 12-week course.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote